Immutep sees first patient dosed in 4th arm of cancer trial

Company News

by Rachael Jones

Biotech company Immutep (ASX:IMM) reports that the first patient in the INSIGHT-004 Phase I clinical trial has received the first dose of treatment in Germany.

INSIGHT-004 is the 4th arm of the INSIGHT trial is being conducted in collaboration with Merck, Darmstadt, Germany and Pfizer Inc.

The study evaluates the safety, tolerability and recommended Phase II dose of Immutep’s lead immunotherapy product candidate efti-lagimod alpha (“efti” or “IMP321”) when administered in combination with avelu-mab (BAVENCIO®) in 12 patients with advanced solid malignancies.

Shares in Immutep (ASX:IMM)

Rachael Jones

Finance News Network
Rachael comes to FNN after working for Fairfax Media covering international breaking news, including the global economy and politics. She joined FNN in February 2018. She has reported on Australia’s finance news for various organisations since 2000 and has also interviewed a number of key business players, including Bill Gates. Rachael has also worked across a number of countries, including the UK and the US.